MedTrace Logo

PGE1 as Additive Anticoagulant in ECMO-Therapy

NCT02895373 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-02-09

No results posted yet for this study

Summary

Bleeding complications and thromboembolic complications are frequent during extracorporeal membrane oxygenation (ECMO). Retrospective data suggest that platelet inhibition using prostaglandins, in this case PGE1, may reduce thromboembolic complications without increasing the bleeding risk. This randomized, double-blind trial aims to investigate the effects of PGE1 on bleeding risk, thromboembolic complications and the function of the ECMO.

Conditions

  • Respiratory Distress Syndrome, Adult
  • Extracorporeal Membrane Oxygenation

Interventions

DRUG

Alprostadil

5ng/kg/min, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy

DRUG

0.9% sodium chloride solution

continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy

Sponsors & Collaborators

  • Thomas Staudinger

    lead OTHER

Principal Investigators

  • Thomas Staudinger, MD · Medical University of Vienna

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2021-05-31
Completion
2021-07-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02895373 on ClinicalTrials.gov